Close this search box.

Amplifying the Voices of Alzheimer’s: ICER Toolkit

Alzheimer’s disease and other forms of dementia have long impacted families
and communities across the country. Today, about 6 million Americans live
with Alzheimer’s disease — a number that will more than double by 2050.

Comments on ICER’s Scoping Document for Hypertrophic Cardiomyopathy Therapy

An efficacious treatment that reduces the symptoms and risk factors associated with obstructive hypertrophic cardiomyopathy delivers great value to patients. Analyses that fail to consider all of the potential benefits, particularly the quality-of-life and productivity benefits, will undervalue this drug. Read the Letter

How ICER Underestimates High Cholesterol

The Institute for Clinical and Economic Review claims that new medications for high cholesterol aren’t worth their cost. The economists overlook the needs of high-risk patients – and underestimate the impact of high cholesterol. View Graphic